KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Retained Earnings (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Retained Earnings for 16 consecutive years, with -$6.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 19317.47% year-over-year to -$6.7 billion, compared with a TTM value of -$6.7 billion through Dec 2025, down 19317.47%, and an annual FY2025 reading of -$6.7 billion, down 19317.47% over the prior year.
  • Retained Earnings was -$6.7 billion for Q4 2025 at Alnylam Pharmaceuticals, up from -$7.2 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$24.8 million in Q3 2024 and bottomed at -$7.4 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$3.0 billion, with a median of -$44.2 million recorded in 2022.
  • The sharpest move saw Retained Earnings surged 99.51% in 2024, then crashed 28742.42% in 2025.
  • Year by year, Retained Earnings stood at -$33.3 million in 2021, then plummeted by 34.26% to -$44.7 million in 2022, then plummeted by 15597.57% to -$7.0 billion in 2023, then soared by 99.51% to -$34.5 million in 2024, then tumbled by 19317.47% to -$6.7 billion in 2025.
  • Business Quant data shows Retained Earnings for ALNY at -$6.7 billion in Q4 2025, -$7.2 billion in Q3 2025, and -$7.4 billion in Q2 2025.